GC Pharma Reports Q1 2018 Results

GC Pharma Reports Q1 2018 Results

(1) Results and percentages compare to equivalent 2017 period. Financial Highlights Delivered total revenues growth of 6.8% to KRW 294.1 billion (Q1 2017: KRW 275.4 billion), driven mainly by strong performance across all businesses. Operating income increased 5.7% to KRW 14.5 billion (Q1 2017: KRW 13.7 billion), primarily due to 0.9% lower cost of sales […]

Eye on Pharma: Biogen Will Increase Its Stake in Samsung Bioepis

Eye on Pharma: Biogen Will Increase Its Stake in Samsung Bioepis

Biogen, one partner in the biosimilar development company Samsung Bioepis, reported total revenues of $3.1 billion in its first quarter 2018 business update call. While most of Biogen’s earnings—up 11% from the same period in 2017—derived from its drugs targeting multiple sclerosis, Jeffrey Capello, executive vice president and chief financial officer, said that biosimilars brought […]

Vertex Pharma Tops Quarterly Views On Strong Cystic Fibrosis Drug Sales

Vertex Pharma Tops Quarterly Views On Strong Cystic Fibrosis Drug Sales

Vertex Pharmaceuticals (VRTX) smashed first-quarter expectations late Thursday, reiterated its 2018 guidance and announced that another triple-pill regimen for cystic fibrosis will head into Phase 3 studies. Having several potential triple-pill combinations allows Vertex to have “multiple shots at the goal,”JMP Securities analyst Liisa Bayko said ahead of the report. Vertex expects to treat 90% […]

Walgreens, Arena Pharma, Dominion Energy: 'Mad Money' Lightning Round

Walgreens, Arena Pharma, Dominion Energy: 'Mad Money' Lightning Round

Here’s what Jim Cramer had to say about some of the stocks during the Mad Money Lightning Round: Walgreens Boots Alliance (WBA) : “I think Walgreens is way too beat up, so I’d say you can buy some.” Arena Pharmaceuticals (ARNA) : “I like specialty pharma. This is a good one, too.” Dominion Energy (D) […]

Formulations for sale: Noramco and SPI Pharma target drugmakers with scalable tech

Formulations for sale: Noramco and SPI Pharma target drugmakers with scalable tech

Under the agreement, Noramco will supply active pharmaceutical ingredients (APIs) and SPI Pharma will provide excipients and co-processed drug delivery platforms. “Both companies will jointly provide ‘proof-of-concept’ formulations that can be tech transferred to customers for scale up,” ​Noramco’s vice president of business development Anthony Ambrosini told us. The offering will include generic, 505(b)(2), and […]

Hyphens Pharma International eyes Catalist IPO

Hyphens Pharma International eyes Catalist IPO

Hyphens Pharma International is seeking a listing on the Catalist board of the Singapore Exchange, with part of the proceeds from the initial public offering to go towards expansion. The pharmaceutical and consumer healthcare group’s core business segments include speciality pharmaceutical products, proprietary brands such as Ceradan and Ocean Health supplements, as well as a […]

Hyphens Pharma International eyes Catalist listing

Hyphens Pharma International eyes Catalist listing

Singapore HYPHENS Pharma International is seeking a listing on the Catalist board of the Singapore Exchange, with part of the proceeds from the inital public offering (IPO) to go towards expansion. The pharmaceutical and consumer healthcare group’s core business segments include Source link

CORRECTED-Vertex Pharma's quarterly profit falls 15.1 percent

CORRECTED-Vertex Pharma's quarterly profit falls 15.1 percent

(Corrects to say revenue fell, not rose, in paragraph 3) April 26 (Reuters) – Vertex Pharmaceuticals Inc’s quarterly profit fell 15.1 percent, hurt by higher research and development spending. Vertex said on Thursday income attributable to the company fell to $210.3 million or 81 cents per share in the three months ended March 31, from […]

UPDATE 1-Vertex Pharma tops profit estimates on strong CF drug sales

UPDATE 1-Vertex Pharma tops profit estimates on strong CF drug sales

(Adds details, background) April 26 (Reuters) – Vertex Pharmaceuticals Inc’s quarterly profit topped analysts’ forecasts, led by double-digit growth in sales of its cystic fibrosis treatments. Vertex mainly sells three types of drugs for the treatment of cystic fibrosis, a rare, life-shortening genetic disease affecting about 75,000 people in North America, Europe and Australia. The […]